Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: A randomized controlled trial

Obstetrics and Gynecology

Volumn 94, Issue 4, 1999, Pages 504-508

  Morrison, Briggs W ^a   Daniels, Stephen E ^b   Kotey, Paul ^a   Cantu, Norma ^b   Seidenberg, Beth ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Premier Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; ROFECOXIB; UNCLASSIFIED DRUG;

ADULT; AGED; ANALGESIC ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSMENORRHEA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OUTPATIENT; PATHOGENESIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CYCLOOXYGENASE INHIBITORS; DYSMENORRHEA; FEMALE; HUMANS; LACTONES; PAIN; SULFONES;

EID: 0032872180     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(99)00360-9     Document Type: Article

References (19)

1. Seibert K., Masferrer J.L. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor. 4:1994;17-23.
2. Smith T.J. Cyclooxygenases as the principal targets for the action of NSAIDs. Rheum Dis Clin North Am. 24:1998;501-523.
3. DeWitt D. Prostaglandin endoperoxide synthase Regulation of enzyme expression . Biochim Biophys Acta. 1083:1991;121-134.
4. Yamagata K., Andreasson K.I., Kaufmann W.E., Barnes C.A., Worley P.F. Expression of a mitogen-inducible cyclooxygenase in brain neurons Regulation by synaptic activity and glucocorticoids . Neuron. 11:1993;371-386.
5. Kömhoff M., Gröne H.-J., Klein T., Seyberth H.W., Nüsing R.M. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney Implication for renal function . Am J Physiol. 272:1997;F460-F468.
6. Gabriel S.E., Jaakkimainen L., Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 15:1991;787-796.
7. Meade E.A., Smith W.L., deWitt D.L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other nonsteroidal anti-inflammatory drugs. J Biol Chem. 268:1993;6610-6614.
8. Bakhle Y.S., Botting R.M. Cyclooxygenase-2 and its regulation in inflammation. Med Inflamm. 1996;305-323.
9. Masferrer J.L., Zweifel B.S., Manning P.T., Hauser S.D., Leahy K.M., Smith W.G., et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and non-ulcerogenic. Proc Natl Acad Sci U S A. 91:1994;3228-3232.
10. Chan C.C., Boyce S., Brideau C., Ford-Hutchinson A.W., Gordon R., Guay D., et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L745.337 - a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther. 273:1995;1531-1537.
11. Dawood M.Y. Nonsteroidal anti-inflammatory drugs and reproduction. Am J Obstet Gynecol. 169:1993;1255-1265.
12. Bieglmayer C., Hofer G., Kainz C., Reinthaller A., Kopp B., Janisch H. Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. Gynecol Endocrinol. 9:1995;307-312.
13. Nigam S., Benedetto C., Zonca M., Leo-Rossberg I., Lubbert H., Hammerstein J. Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhea. Eicosanoids. 4:1991;137-141.
14. Chan W.Y., Dawood M.Y., Fuchs F. Relief of dysmenorrhea with the prostaglandin synthetase inhibitor ibuprofen Effect on prostaglandin levels in menstrual fluid . Am J Obstet Gynecol. 135:1979;1255-1265.
15. Chan W.Y., Fuchs F., Powell A.M. Effects of naproxen sodium on menstrual prostaglandins and primary dysmenorrhea. Obstet Gynecol. 61:1983;285-291.
16. Lim H., Paria B.C., Das S.K., Dinchuk J.E., Langenbach R., Trzaskos J.M., et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell. 91:1997;197-208.
17. Ehrich E.W., Dallob A., de Lepeleire I., van Hecken A., Riendeau D., Yuan W., et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther. 65:1999;336-347.
18. Mehlisch D.R., Fulmer R.I. A crossover comparison of bromfenac sodium, naproxen sodium, and placebo for relief of pain from primary dysmenorrhea. J Womens Health. 6:1997;83-92.
19. Ehrich E, Schnitzer T, Kivitz A, Weaver A, Wolfe F, Morrison B, et al. MK-966, a highly selective Cox-2 inhibitor, was effective in the treatment of osteoarthritis (OA) of the knee and hip in a 6-week placebo controlled study. J Rheum (in press).